ASTELLAS PHARMA TO ACQUIRE IVERIC BIO IN $5.9 BILLION DEAL

3 May 2023

On April 30th, 2023, Astellas Pharma Inc announced that it will acquire Iveric bio Inc for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion.

Iveric Bio focuses on the discovery and development of novel treatments in the field of ophthalmology.

More, Source: Company’s Press Release